Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

AstraZeneca Expands Frederick-Gaithersburg Maryland, Manufacturing Operations

11/29/2025
Global biopharmaceutical company AstraZeneca plans to expand its operations in Frederick and Gaithersburg Maryland. The approximately $1.8 billion project is expected to create 300 jobs.

The investment will include the construction of a new production facility in Gaithersburg and an expansion of the company’s existing biologics manufacturing site in Frederick. Operations are scheduled to begin in 2029.

“Today marks a landmark moment for Maryland and American patients,” said AstraZeneca Chief Executive Officer Pascal Soriot. “As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland—supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the U.S. medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”

To support the project the state is providing a roughly 10% investment match of total project costs.

“AstraZeneca has long been a vital partner to the state of Maryland’s and one of the most valued members of our business community. They have created thousands of good jobs for Maryland residents and helped make our state a world leader in life sciences innovation,” noted Maryland Department of Commerce Secretary Harry Coker, Jr. “We are beyond thrilled that AstraZeneca has once again chosen to invest and grow in Maryland. This is the start of a bold new chapter for the company, the state, and for Frederick and Montgomery Counties. We at Maryland Commerce look forward to working with all of our partners to support this landmark project.”

AstraZeneca develops and sells medicines for a wide range of diseases in areas like oncology, cardiovascular, respiratory, and rare diseases.

“We are thrilled that AstraZeneca has once again chosen to invest in Montgomery County and in the state of Maryland,” added Elana Fine, board chair of the Montgomery County Economic Development Corporation (MCEDC). “The company’s continued investment underscores the unparalleled life sciences ecosystem we’ve built here in Montgomery County. With cutting-edge therapies being researched and developed right here, this investment further cements our unique position to support global organizations like AstraZeneca. We look forward to deepening our partnership and continuing to support their groundbreaking work.”

“Bio pharmaceutical and advanced manufacturing continue to be very strong industry sectors for the City of Frederick and our region,” said Richard Griffin, Director of Economic Development for the City of Frederick. “The announcement by AstraZeneca to expand its footprint and product manufacturing in Frederick follows decades of investment and growth at this campus and the City looks to a long-future together for the benefit of our resident workers and region.”

Exclusive Research